Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin

被引:20
|
作者
Joel, SP [1 ]
Papamichael, D
Richards, F
Davis, T
Aslanis, V
Chatelut, E
Locke, K
Slevin, ML
Seymour, MT
机构
[1] St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, England
[2] Cookridge Hosp, Canc Res UK Med Oncol Unit, Leeds, W Yorkshire, England
[3] Univ Toulouse 3, F-31062 Toulouse, France
[4] Inst Claudius Regaud, Toulouse, France
关键词
D O I
10.1016/j.clpt.2004.03.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Our objective was to investigate the influence of oxaliplatin on the pharmacokinetics of 5-fluorouracil (5FU) administered in a bolus plus infusional regimen. Patients and Methods. All patients had advanced/metastatic colorectal cancer. In study 1, 19 patients were studied after bolus (400 mg/m(2)) plus a 22-hour infusion (600 mg/m(2)) of 5FU/leucovorin in the standard de Gramont regimen or the same regimen with oxaliplatin (85 mg/m(2)) given before 5FU. In study 2, 12 patients were studied for 2 treatment cycles, with 5FU given in a modified de Gramont regimen comprising bolus (400 mg/m(2)) plus a 46-hour infusion (2400 mg/m(2)) of 5FU. During 1 of these cycles, oxaliplatin (85 mg/m(2)) was given before 5FU. Results. The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L (.) h(-1), 14.9 +/- 4.2 mg (.) h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L (.) h(-1), 13.3 +/- 2.3 mg (.) h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg (.) h/L, 35.4 +/- 4.2 mg (.) h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg (.) h/L, 38.1 +/- 7.4 mg (.) h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin). The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg (.) h(-1)), day 1 Michaelis-Menten constant (7.8 mg (.) h(-1)), and day 2 Michaelis-Menten constant (11.9 mg (.) h(-1)). Conclusions. The coadministration of oxaliplatin in either the standard or modified de Gramont regimen does not significantly affect the pharmacokinetics of 5FU.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 50 条
  • [1] Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP).
    Papamichael, D
    Joel, SP
    Seymour, M
    Richards, F
    Bowerbank, M
    Slevin, ML
    BRITISH JOURNAL OF CANCER, 1998, 78 : 12 - 12
  • [2] Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase
    Yamazaki, S
    Hayashi, M
    Toth, LN
    Ozawa, N
    XENOBIOTICA, 2001, 31 (01) : 25 - 31
  • [3] Docetaxel, oxaliplatin and 5-fluorouracil: A phase I, pharmacokinetic and pharmacogenomic study
    Mulcahy, M.
    Hochster, H.
    Ryan, T.
    Avram, M.
    Kolesar, J.
    Benson, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 96 - 96
  • [4] Synergistic interaction between oxaliplatin (L-OHP) and 5-Fluorouracil (5-FU)
    Ward, S
    Papamichael, D
    Locke, K
    Darke, C
    Joel, S
    ANNALS OF ONCOLOGY, 1998, 9 : 39 - 39
  • [5] PHARMACOKINETIC RATIONALE FOR THE INTERACTION OF 5-FLUOROURACIL AND MISONIDAZOLE IN HUMANS
    MCDERMOTT, BJ
    VANDENBERG, HW
    MARTIN, WMC
    MURPHY, RF
    BRITISH JOURNAL OF CANCER, 1983, 48 (05) : 705 - 710
  • [6] Interaction of quercetin and 5-fluorouracil: cellular and pharmacokinetic study
    Pirzaman, Ali Tavakoli
    Aghajanian, Soheyla
    Mansoori, Razieh
    Al-e-Ahmad, Atiyeh
    Ebrahimzadeh, Manijeh
    Moghadamnia, Ali Akbar
    Kazemi, Sohrab
    TOXICOLOGY MECHANISMS AND METHODS, 2023, 33 (06) : 502 - 511
  • [7] PHARMACOKINETIC ANALYSIS OF INTERACTION OF SODIUM WARFARIN WITH 5-FLUOROURACIL
    CHAN, K
    CHLEBOWSKI, R
    GOTA, C
    BATEMAN, J
    CLINICAL RESEARCH, 1978, 26 (02): : A100 - A100
  • [8] INTERACTION BETWEEN CEPHALOSPORINS AND 5-FLUOROURACIL
    BOSSA, R
    ARESCA, P
    BAGGIO, G
    CASTELLI, M
    GALATULAS, I
    NINCI, MA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (04) : 1195 - 1196
  • [9] INTERACTION BETWEEN 5-FLUOROURACIL AND BACTERIAL ENDOTOXIN
    MUNSON, AE
    FRIEDMAN, MA
    WATT, K
    PHARMACOLOGIST, 1974, 16 (02): : 253 - 253
  • [10] Lethal interaction between 5-fluorouracil and brivudine
    Garcia Herrera, A. N.
    Moncayola Vicen, J. C.
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2018, 41 (02) : 277 - 278